Improving therapeutic strategies for secondary bacterial pneumonia following influenza

Future Microbiology

Volumn 3, Issue 4, 2008, Pages 397-404

  McCullers, Jonathan A ^a   English, B Keith ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

Antibiotic; Influenza virus; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

ACTIVATED PROTEIN C; AMANTADINE; AMPICILLIN; ANTIVIRUS AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; INACTIVATED VACCINE; INFLUENZA VACCINE; MACROLIDE; OSELTAMIVIR; PENICILLIN G; PNEUMOCOCCUS VACCINE; RIFAMPICIN; RIMANTADINE; SIALIDASE INHIBITOR; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL SUPERINFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FATALITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INFLUENZA; INFLUENZA VACCINATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; SECONDARY INFECTION; SEPSIS; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; PNEUMONIA, BACTERIAL;

BACTERIA (MICROORGANISMS); ORTHOMYXOVIRIDAE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 48749125493     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.4.397     Document Type: Article

References (53)

1. McCullers JA: Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19(3), 571-582 (2006).
2. Morens DM, Fauci AS: The 1918 influenza pandemic: insights for the 21st century. J. Infect. Dis. 195(7), 1018-1028 (2007).
3. Minino AM, Heron MP, Murphy SL, Kochanek KD: Deaths: final data for 2004. Natl Vital Stat. Rep. 55 (19), 1-119 (2007).
4. World Health Organization. The World Health Report 2005: make every mother and child count. 1-243 (2005).
5. Scaddirig JG: Lung changes in influenza. Quart. J. Med. 6425-6465 (1937).
6. Louria D, Blumenfeld H, Ellis J, Kilbourne ED, Rogers D: Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J. Clin. Invest. 38, 213-265 (1959).
7. Stuart-Haris CH, Laird J, Tyrrell DA, Kelsall MH, Franks ZC: The relationship between influenza and pneumonia. J. Hyg. (Lond.) 47(4), 434-448 (1949).
8. McCullers JA: Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J. Infect. Dis. 190(3), 519-526 (2004).
9. McCullers JA, Rehg JE: Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis. 186(3), 341-350 (2002).
10. McCullers JA, Bartmess KC: Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J. Infect. Dis. 187(6), 1000-1009 (2003).
11. CDC: Influenza-associated pediatric mortality and Stapbylococcus aureus co-infection (2008).
12. Austrian R, Gold J: Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 60(5), 759-776 (1964).
13. Mandell LA, Wunderink RG, Anzueto A et al.: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl, 2), S27-S72 (2007).
14. Whitney CG, Farley MM, Hadler J et al.: Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343(26), 1917-1924 (2000).
15. English BK, Buckingham SC: Impact of antimicrobial resistance on therapy of bacterial pneumonia in children. Adv. Exp. Med. Biol. 582, 125-135 (2006).
16. Feikin DR, Schuchat A, Kolczak M et al.: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90(2), 223-229 (2000).
17. Yu VL, Chiou CC, Feldman C et al.: An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered and clinical outcome. Clin. Infect. Dis. 37(2), 230-237 (2003).
18. Pallares R, Linares J, Vadillo M et al.: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333(8), 474-480 (1995).
19. Buckingham SC, McDougal LK, Cathey LD et al.: Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee Children's Hospital. Pediatr. Infect. Dis. J. 23(7), 519-624 (2004).
20. Kaplan SL: Community-acquired methicillin-resistant Staphylococcus aureus infections in children. Semin. Pediatr. Infect. Dis. 17(3), 113-119 (2006).
21. CDC: Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus. Minnesota and North Dakota, 1997-1999. JAMA 282(12), 1123-1125 (1999).
22. Gonzalez BE, Hulten KG, Dishop MK et al.: Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin. Infect. Dis. 41(5), 583-590 (2005).
23. Francis JS, Doherty MC, Lopatin U et al.: Severe community-onset pneumonia in healthy adults caused by methicillin- resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin. Infect. Dis. 40(1), 100-107 (2005).
24. CDC: Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza: Louisiana and Georgia, December 2006-January 2007. Morb. Mortal. Wkly Rep. 56(14), 325-329 (2007).
25. Nichol KL, Nordin JD, Nelson DB, Mulloolv JP, Hak F Effectiveness of influenza vaccine in t lie community- dwelling elderly. N. Engl. J. Med. 357(14), 1373-1381 (2007).
26. Madhi SA, Klugman KP: A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 10(8), 811-813 (2004).
27. Peltola VT, McCullers JA: Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr. Infect. Dis. J. 23(Suppl. 1), S87-S97 (2004).
28. Whitley RJ, Hayden FG, Reisinger KS et al.: Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20(2), 127-133 (2001).
29. Treanor JJ, Hayden FG, Vrooman PS et al.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283(8), 1016-1024 (2000).
30. Monto AS: The role of antivirals in the control of influenza. Vaccine 21(16), 1796-1800 (2003).
31. van der Poll T, Keogla CV, Guirao, X, Buurman WA, Kopf M, Lowry SF: Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 176(2), 439-444 (1997).
32. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF: Interleukin-10 impairs host defense in routine pneumococcal pneumonia. J. Infect. Dis. 174(5), 994-1000 (1996).
33. Bone RC: Sir Isaac Newton, sepsis, SIRS and CARS. Crit. Care Med. 24(7), 1125-1128 (1996).
34. McCullers JA, Tuomanen EI: Molecular pathogenesis of pneamococcal pneumonia. Front. Biosci. 6, D877-D889 (2001).
35. Nau R, Eiffert H: Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin. Microbiol. Rev. 15(1), 95-110 (2002).
36. Orman KL, English BK: Effects of antibiotic class on the macrophage inflammatory response to stneptococcus pneumoniae. J. Infect. Dis. 182(5), 1561-1565 (2000).
37. Brinkmann KC, Talati AJ, Akbari RE, Meals EA, English BK: Group B streptococci exposed to rifampin or clindamycin (versus ampicillin or cefotaxime) stimulate reduced production of inflammatory mediators by murine macrophages. Pediatr. Res. 57(3), 419-423 (2005).
38. English BK, Maryniw EM, Talati AJ, Meals EA: Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin. Antimicrob. Agents Chemother. 50(6), 2225-2227 (2006).
39. Buckingham SC, McCullers JA, Lujan-Zilbermann J, Knapp KM, Orman KL, English BK: Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. Pediatrics 117 (5), 1688-1694 (2006).
40. Karlstrom A, English BK, McCullers JA: Outcomes from secondary pneumococcal pneumonia following influenza are improved by treatment with a protein synthesis inhibitor. (2008) (In Press).
41. Martinez JA, Horcajada JP, Almela M et al.: Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 36(4), 389-395 (2003).
42. Garcia VE, Mensa J, Martinez JA et al.: Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone. Eur. J. Clin. Microbiol. Infect. Dis. 24(3), 190-195 (2005).
43. Baddour LK Yu VL, Klugman KP et al.: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. 170(4), 440-444 (2004).
44. File TM Jr, Mandell LA: What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin. Infect. Dis. 36(4), 396-398 (2003).
45. McAuley JL, Horung F, Boyd KL, et al.: PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2(4), 240-249 (2007).
46. Cheung CY, Poon LL, Lau AS et al.: Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360(9348), 1831-1837 (2002).
47. de Jong MD, Simmons CP, Thanh.TT et al.: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12(10), 1203-1207 (2006).
48. Comeau JL, Lin TJ, Marken MB et al.: Staphylococcal pericarditis, and liver and paratracheal abscesses as presentations in two new cases of interleukin-1 receptor-associated kinase 4 deficiency. Pediatr. Infect. Dis. J. 27(2), 170-174 (2008).
49. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis ano septic shock. Clin. Infect. Dis. 34(8), 1084-1093 (2002)
50. Steinberg KP, Hudson LD, Goodman RB et al.: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 354(16), 1671-1684 (2006).
51. Smith MW, Schmidt JE, Rehg JE, Orthuela C, McCullers JA: Induction of pro- and anti -inflammatory molecules in a mouse model of pneumococcal pneumonia following influenza. Comp. Med. 57(1), 12-18 (2007).
52. McCullers JA: A dysfunctional innate immune response contributes to pneumococcal pneumonia following influenza. Presented at: Infectious Diseases Society of America, 43rd Annual Meeting. 6-9 October, San Francisco, CA, USA (2005).
53. Dethlefsen L, Fall-Ngai M, Relman DA: An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449(7164), 811-818 (2007).